The mobile X-Ray unit DR 100s Pro reportedly offers an array of attributes to facilitate workflow efficiencies and quality imaging.
News|Slideshows|December 24, 2024
Video Interview Highlights from RSNA 2024
Author(s)Jeff Hall
Catch up on video interviews from the recent 2024 Radiological Society of North America (RSNA) conference.
Advertisement
As we come to the end of 2024, we take a look back at video interviews from the 2024 Radiological Society of North America (RSNA) conference with topics ranging from AI in breast imaging to cybersecurity to an emerging MRI research showing a link between skeletal bone loss and dementia. Review the slideshow to view highlighted video interviews from the RSNA conference.
Advertisement
Related to this article
In a recent interview, Gadi Lalazar, MD, discussed new research demonstrating the capability of natural language processing (NLP) to enhance recognition of incidental hepatic steatosis in ultrasound reports.
Report One, reportedly the first agentic reporting tool specifically geared to breast imaging, is one of three new products that will be showcased by MagView at the upcoming RSNA conference.
Artificial intelligence plaque analysis of CCTA scans showed that 27 percent of former NFL players had severe or extensive total plaque volume, according to a new study to be presented at the American Heart Association Scientific Sessions 2026 this week.
New research suggests CCTA may provide salient preoperative insights into planning for percutaneous coronary intervention (PCI) while facilitating similar outcomes as intravascular ultrasound guidance for target-vessel failure.
In a recent interview with Diagnostic Imaging, Eliad Josephson discussed key attributes of the HLTH USA conference, AI trends and an ongoing shift of emphasis on the development of predictive technologies with diagnostics at center stage.
Through enhanced insights into atherosclerotic disease, complex coronary lesions and coronary stents, photon-counting CT provides an anatomical roadmap that may improve outcomes for interventional procedures.
The PSMA PET radiopharmaceutical 64Cu-SAR-bisPSMA, which previously garnered two FDA fast track designations, more than doubled the detection of PCa lesions in comparison to 68Ga-PSMA-11 in the phase II Co-PSMA trial.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Issues Breakthrough Therapy Designation for Emerging PSMA PET Agent in Men with Suspected PCa Recurrence
2
Agfa Radiology to Introduce AI-Powered DR 100s Pro X-Ray Platform at RSNA
3
CMS Reverses Decision and Issues New Outpatient CPT Code for Ultrasound-Based QTscan
4
Could an Emerging NacBI-RADS System for mpMRI Bolster Assessment of NAC Response?
5